Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.

Ther Adv Endocrinol Metab · 2026 · PMC13332288 · PMID 42404804

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The MAKE hazard ratio for empagliflozin versus sitagliptin did not reach statistical significance, whereas the corresponding 24-month absolute risk difference did exclude zero; this reflects a modest relative hazard acting on a high baseline event rate and not a data inconsistency.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.